Key Segments
By Product Type
-
Theranostic Pairs
-
Diagnostic Radiopharmaceuticals
-
Therapeutic Radiopharmaceuticals
By Radioisotope
-
Lutetium-177 (Lu-177)
-
Gallium-68 (Ga-68)
-
Actinium-225
-
Yttrium-90
-
Iodine-131
By Application
-
Oncology
-
Cardiology
-
Neurology
By End User
-
Hospitals
-
Specialty Cancer Centers
-
Diagnostic Imaging Centers
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Ans: North America dominated the Radiopharmaceutical Theranostics Market in 2025.
Ans: The “Theranostic Pairs” segment dominated during the projected period.
Ans: The key drivers of the Radiopharmaceutical Theranostics Market include rising cancer prevalence, growing adoption of precision oncology, increasing use of Lu-177 and alpha-emitter therapies, expanding nuclear medicine infrastructure, favorable regulatory approvals, and investment in advanced radiopharmaceutical research and clinical trials.
Ans: The market was valued at USD 2.42 Billion in 2025 and is projected to reach USD 6.93 Billion by 2035.
Ans: The Radiopharmaceutical Theranostics Market is expected to grow at a CAGR of 11.14% during 2026–2035.